Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms

Amaç: Polisitemia vera (PV), esansiyel trombositemi (ET) ve primer miyelofibrozu (PMF) içeren kronik miyeloproliferatif neoplaziler (KMPN), bir ya da birden fazla serinin klonal proliferasyonu ile karakterize Philadelphia kromozomu negatif olan malignitelerdir. Bu çalışmanın amacı, Türkiye'de KMPN'li hastaların demografik özellikleri, hastalık karakteristikleri, tedavi stratejileri ve yaşam oranlarını belirlemektir.Gereç ve Yöntemler: Türkiye'nin her yanından 9 merkez çalışmaya katıldı. Biz geriye dönük olarak ET'li 390, PV'li 213 ve PMF'li 105 hasta olmak üzere toplam 708 KMPN'li hastanın verisini değerlendirdik. Bulgular: JAK-2 mutasyonu PV'li hastaların %86'sında, ET'li hastaların %51,5'inde ve PMF'li hastaların %50,4'ünde pozitif bulundu. Tanıda tromboz ve kanama, PV'li hastaların sırasıyla %20,6 ve %7,5'inde, ET'li hastaların %15,1 ve %9'unda ve PMF'li hastaların %9,5 ve %10,4'ünde saptandı. Altı yüz sekiz hasta (%85,9) sitoredüktif tedavi almıştı. En sık kullanılan ilaç hidroksiüre (%89,6) idi. Lösemik ve fibrotik transformasyon sıklığı %0,6 ve %13,2 idi. 10 yıllık hesaplanan toplam sağkalım PV, ET ve PMF hastalarında sırasıyla %89,7, %85 ve %82,5 idi. 10 yıllık toplam sağkalım açısından ET, PV ve PMF hastalarında anlamlı fark yoktu.Sonuç: Sonuçlarımız, PMF hastalarının yüksek sağkalımı hariç literatürle benzerdir. Hidroksiüre ülkemizdeki en sık kullanılan sitoredüktif ajandır. Bizim çalışmamız, Türk KMPN hastalarının demografik özelliklerini, hastaların karakteristiklerini, tedavilerini ve sağkalım oranlarını yansıtmaktadır

Anahtar Kelime:

Konular: Hematoloji

Kronik Miyeloproliferatif Neoplazi Tanılı Türk Hastaların Geriye Dönük ve Çok Merkezli Analizi

Öz:

Objective: Chronic myeloproliferative neoplasms (CMPNs) that include polycythemia vera (PV), essential thrombocythemia (ET), and primary myelofibrosis (PMF) are Philadelphia-negative malignancies characterized by a clonal proliferation of one or several lineages. The aim of this report was to determine the demographic features, disease characteristics, treatment strategies, and survival rates of patients with CMPNs in Turkey. Materials and Methods: Across all of Turkey, 9 centers were enrolled in the study. We retrospectively evaluated 708 CMPN patients’ results including 390 with ET, 213 with PV, and 105 with PMF. Results: The JAK2V617F mutation was found positive in 86% of patients with PV, in 51.5% of patients with ET, and in 50.4% of patients with PMF. Thrombosis and bleeding at diagnosis occurred in 20.6% and 7.5% of PV patients, 15.1% and 9% of ET patients, and 9.5% and 10.4% of PMF patients, respectively. Six hundred and eight patients (85.9%) received cytoreductive therapy. The most commonly used drug was hydroxyurea (89.6%). Leukemic and fibrotic transformations occurred at rates of 0.6% and 13.2%. The estimated overall survival in PV, ET, and PMF patients was 89.7%, 85%, and 82.5% at 10 years, respectively. There were no significant differences between survival in ET, PV, and PMF patients at 10 years. Conclusion: Our patients’ results are generally compatible with the literature findings, except for the relatively high survival rate in PMF patients. Hydroxyurea was the most commonly used cytoreductive therapy. Our study reflects the demographic features, patient characteristics, treatments, and survival rates of Turkish CMPN patients

Anahtar Kelime:

Konular: Hematoloji

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

Tefferi A, Vardiman JW. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia 2008;22:14-22.
Barbui T, Finazzi G, Falanga A. Myeloproliferative neoplasms and thrombosis. Blood 2013;122:2176-2184.
Tefferi A, Vainchenker W. Myeloproliferative neoplasms: molecular pathophysiology, essential clinical understanding, and treatment strategies. J Clin Oncol 2011;29:573-582.
Tefferi A. Myeloproliferative neoplasms 2012: the John M. Bennett 80th birthday anniversary lecture. Leuk Res 2012;36:1481-1489.
Tefferi A, Barbui T. Polycythemia vera and essential thrombocythemia: 2015 update on diagnosis, risk-stratification and management. Am J Hematol 2015;90:162-173.
Marchioli R, Finazzi G, Landolfi R, Kutti J, Gisslinger H, Patrono C, Marilus R, Villegas A, Tognoni G, Barbui T. Vascular and neoplastic risk in a large cohort of patients with polycythemia vera. J Clin Oncol 2005;23:2224-2232.
Gruppo Italiano Studio Policitemia. Polycythemia vera: the natural history of 1213 patients followed for 20 years. Ann Intern Med 1995;123:656-664.
Elliott MA, Tefferi A. Thrombosis and hemorrhage in polycythemia vera and essential thrombocythemia. Br J Haematol 2005;128:275-290.
Landolfi R, Marchioli R, Kutti J, Gisslinger H, Tognoni G, Patrono C, Barbui T; European Collaboration on Low-Dose Aspirin in Polycythemia Vera Investigators. Efficacy and safety of low dose aspirin in polycythemia vera. N Engl J Med 2004;350:114-124.
Landolfi R, Di Gennaro L, Barbui T, De Stefano V, Finazzi G, Marfisi R, Tognoni G, Marchioli R; European Collaboration on Low-Dose Aspirin in Polycythemia Vera (ECLAP). Leukocytosis as a major thrombotic risk factor in patients with polycythemia vera. Blood 2007;109:2446-2452.
Wolanskyj AP, Schwager SM, McClure RF, Larson DR, Tefferi A. Essential thrombocythemia beyond the first decade: life expectancy, long term complication rates, and prognostic factors. Mayo Clin Proc 2006;81:159- 166.
Carobbio A, Finazzi G, Guerini V, Spinelli O, Delaini F, Marchioli R, Borrelli G, Rambaldi A, Barbui T. Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status. Blood 2007;109:2310-2313.
Palandri F, Polverelli N, Catani L, Ottaviani E, Baccarani M, Vianelli N. Impact of leukocytosis on thrombotic risk and survival in 532 patients with essential thrombocythemia: a retrospective study. Ann Hematol 2011;90:933-938.
Cervantes F, Alvarez-Larrán A, Arellano-Rodrigo E, Granell M, Domingo A, Montserrat E. Frequency and risk factors for thrombosis in idiopathic myelofibrosis: analysis in a series of 155 patients from a single institution. Leukemia 2006;20:55-60.
Barbui T, Carobbio A, Cervantes F, Vannucchi AM, Guglielmelli P, Antonioli E, Alvarez-Larrán A, Rambaldi A, Finazzi G, Barosi G. Thrombosis in primary myelofibrosis: incidence and risk factors. Blood 2010;115:778-782.
Tefferi A, Rumi E, Finazzi G, Gisslinger H, Vannucchi AM, Rodeghiero F, Randi ML, Vaidya R, Cazzola M, Rambaldi A, Gisslinger B, Pieri L, Ruggeri M, Bertozzi I, Sulai NH, Casetti I, Carobbio A, Jeryczynski G, Larson DR, Müllauer L, Pardanani A, Thiele J, Passamonti F, Barbui T. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 2013;27:1874-1881.
Chim CS, Kwong YL, Lie AK, Ma SK, Chan CC, Wong LG, Kho BC, Lee HK, Sim JP, Chan CH, Chan JC, Yeung YM, Law M, Liang R. Long-term outcome of 231 patients with essential thrombocythemia: prognostic factors for thrombosis, bleeding, myelofibrosis, and leukemia. Arch Intern Med 2005;165:2651-2658.
Tefferi A, Guglielmelli P, Larson DR, Finke C, Wassie EA, Pieri L, Gangat N, Fjerza R, Belachew AA, Lasho TL, Ketterling RP, Hanson CA, Rambaldi A, Finazzi G, Thiele J, Barbui T, Pardanani A, Vannucchi AM. Long-term survival and blast transformation in molecularly annotated essential thrombocythemia, polycythemia vera, and myelofibrosis. Blood 2014;124:2507-2513.
Gangat N, Strand J, Li CY, Wu W, Pardanani A, Tefferi A. Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation. Br J Haematol 2007;138:354-358.
Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M, Morra E, Lazzarino M. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004;117:755-761.
Gangat N, Wolanskyj AP, McClure RF, Li CY, Schwager S, Wu W, Tefferi A. Risk stratification for survival and leukemic transformation in essential thrombocythemia: a single institutional study of 605 patients. Leukemia 2007;21:270-276.
Passamonti F, Rumi E, Arcaini L, Boveri E, Elena C, Pietra D, Boggi S, Astori C, Bernasconi P, Varettoni M, Brusamolino E, Pascutto C, Lazzarino M. Prognostic factors for thrombosis, myelofibrosis, and leukemia in essential thrombocythemia: a study of 605 patients. Haematologica 2008;93:1645- 1651.
Gangat N, Caramazza D, Vaidya R, George G, Begna K, Schwager S, Van Dyke D, Hanson C, Wu W, Pardanani A, Cervantes F, Passamonti F, Tefferi A. DIPSS Plus: A refined Dynamic International Prognostic Scoring System for primary myelofibrosis that incorporates prognostic information from karyotype, platelet count, and transfusion status. J Clin Oncol 2011;29:392- 397.
Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, Harris NL, Le Beau MM, Hellström-Lindberg E, Tefferi A, Bloomfield CD. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood 2009;114:937-951.
Cervantes F, Dupriez B, Pereira A, Passamonti F, Reilly JT, Morra E, Vannucchi AM, Mesa RA, Demory JL, Barosi G, Rumi E, Tefferi A. New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment. Blood 2009;113:2895-2901.
Barbui T, Barosi G, Birgegard G, Cervantes F, Finazzi G, Griesshammer M, Harrison C, Hasselbalch HC, Hehlmann R, Hoffman R, Kiladjian JJ, Kröger N, Mesa R, McMullin MF, Pardanani A, Passamonti F, Vannucchi AM, Reiter A, Silver RT, Verstovsek S, Tefferi A; European LeukemiaNet. Philadelphia- negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet. J Clin Oncol 2011;29:761-770.
Landolfi R, Di Gennaro L, Falanga A. Thrombosis in myeloproliferative disorders: pathogenetic facts and speculation. Leukemia 2008;22:2020- 2028.
Passamonti F, Elena C, Schnittger S, Skoda RC, Green AR, Girodon F, Kiladjian JJ, McMullin MF, Ruggeri M, Besses C, Vannucchi AM, Lippert E, Gisslinger H, Rumi E, Lehmann T, Ortmann CA, Pietra D, Pascutto C, Haferlach T, Cazzola M. Molecular and clinical features of the myeloproliferative neoplasm associated with JAK2 exon 12 mutations. Blood 2011;117:2813-2816.
Langabeer SE, Andrikovics H, Asp J, Bellosillo B, Carillo S, Haslam K, Kjaer L, Lippert E, Mansier O, Oppliger Leibundgut E, Percy MJ, Porret N, Palmqvist L, Schwarz J, McMullin MF, Schnittger S, Pallisgaard N, Hermouet S; MPN&MPNr-EuroNet. Molecular diagnostics of myeloproliferative neoplasms. Eur J Haematol 2015;95:270-279.
Hultcrantz M, Kristinsson SY, Andersson TM, Landgren O, Eloranta S, Derolf AR, Dickman PW, Björkholm M. Patterns of survival among patients with myeloproliferative neoplasms diagnosed in Sweden from 1973 to 2008: a population-based study. J Clin Oncol 2012;30:2995-3001.
Rollison DE, Howlader N, Smith MT, Strom SS, Merritt WD, Ries LA, Edwards BK, List AF. Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs. Blood 2008;112:45-52.
Maynadié M, Girodon F, Manivet-Janoray I, Mounier M, Mugneret F, Bailly F, Favre B, Caillot D, Petrella T, Flesch M, Carli PM. Twenty-five years of epidemiological recording on myeloid malignancies: data from the specialized registry of hematologic malignancies of Cote d’Or (Burgundy, France). Haematologica 2011;96:55-61.
Malak S, Labopin M, Saint-Martin C, Bellanne-Chantelot C, Najman A; French Group of Familial Myeloproliferative Disorders. Long term follow up of 93 families with myeloproliferative neoplasms: life expectancy and implications of JAK2V617F in the occurrence of complications. Blood Cells Mol Dis 2012;49:170-176.
Cervantes F, Dupriez B, Passamonti F, Vannucchi AM, Morra E, Reilly JT, Demory JL, Rumi E, Guglielmelli P, Roncoroni E, Tefferi A, Pereira A. Improving survival trends in primary myelofibrosis: an international study. J Clin Oncol 2012;30:2981-2987.
Passamonti F, Rumi E, Pungolino E, Malabarba L, Bertazzoni P, Valentini M, Orlandi E, Arcaini L, Brusamolino E, Pascutto C, Cazzola M, Morra E, Lazzarino M. Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia. Am J Med 2004;117:755-761.
Xu Z, Gale RP, Zhang Y, Qin T, Chen H, Zhang P, Zhang T, Liu L, Qu S, Xiao Z. Unique features of primary myelofibrosis in Chinese. Blood 2012;119:2469- 2473.
Khanal N, Giri S, Upadhyay S, Shostrom VK, Pathak R, Bhatt VR. Risk of second primary malignancies and survival of adult patients with polycythemia vera: a United States population-based retrospective study. Leuk Lymphoma 2016;57:129-133.
Stein BL, Moliterno AR, Tiu RV. Polycythemia vera disease burden: contributing factors, impact on quality of life, and emerging treatment options. Ann Hematol 2014;93:1965-1976.

APA	SOYER N, HAZNEDAROĞLU İ, Cömert M, ÇEKDEMIR D, YILMAZ M, ÜNAL A, AKGÜN ÇAĞLIYAN G, Bilgir O, ilhan o, Gediz F, KAYA E, Sahin F, vural f, SAYDAM G (2017). Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. , 27 - 33.
Chicago	SOYER Nur,HAZNEDAROĞLU İbrahim C.,Cömert Melda,ÇEKDEMIR DEMET,YILMAZ MEHMET,ÜNAL Ali,AKGÜN ÇAĞLIYAN GÜLSÜM,Bilgir Oktay,ilhan osman,Gediz Fusun,KAYA Emin,Sahin Fahri,vural filiz,SAYDAM Güray Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. (2017): 27 - 33.
MLA	SOYER Nur,HAZNEDAROĞLU İbrahim C.,Cömert Melda,ÇEKDEMIR DEMET,YILMAZ MEHMET,ÜNAL Ali,AKGÜN ÇAĞLIYAN GÜLSÜM,Bilgir Oktay,ilhan osman,Gediz Fusun,KAYA Emin,Sahin Fahri,vural filiz,SAYDAM Güray Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. , 2017, ss.27 - 33.
AMA	SOYER N,HAZNEDAROĞLU İ,Cömert M,ÇEKDEMIR D,YILMAZ M,ÜNAL A,AKGÜN ÇAĞLIYAN G,Bilgir O,ilhan o,Gediz F,KAYA E,Sahin F,vural f,SAYDAM G Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. . 2017; 27 - 33.
Vancouver	SOYER N,HAZNEDAROĞLU İ,Cömert M,ÇEKDEMIR D,YILMAZ M,ÜNAL A,AKGÜN ÇAĞLIYAN G,Bilgir O,ilhan o,Gediz F,KAYA E,Sahin F,vural f,SAYDAM G Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. . 2017; 27 - 33.
IEEE	SOYER N,HAZNEDAROĞLU İ,Cömert M,ÇEKDEMIR D,YILMAZ M,ÜNAL A,AKGÜN ÇAĞLIYAN G,Bilgir O,ilhan o,Gediz F,KAYA E,Sahin F,vural f,SAYDAM G "Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms." , ss.27 - 33, 2017.
ISNAD	SOYER, Nur vd. "Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms". (2017), 27-33.

APA	SOYER N, HAZNEDAROĞLU İ, Cömert M, ÇEKDEMIR D, YILMAZ M, ÜNAL A, AKGÜN ÇAĞLIYAN G, Bilgir O, ilhan o, Gediz F, KAYA E, Sahin F, vural f, SAYDAM G (2017). Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. Turkish Journal of Hematology, 34(1), 27 - 33.
Chicago	SOYER Nur,HAZNEDAROĞLU İbrahim C.,Cömert Melda,ÇEKDEMIR DEMET,YILMAZ MEHMET,ÜNAL Ali,AKGÜN ÇAĞLIYAN GÜLSÜM,Bilgir Oktay,ilhan osman,Gediz Fusun,KAYA Emin,Sahin Fahri,vural filiz,SAYDAM Güray Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. Turkish Journal of Hematology 34, no.1 (2017): 27 - 33.
MLA	SOYER Nur,HAZNEDAROĞLU İbrahim C.,Cömert Melda,ÇEKDEMIR DEMET,YILMAZ MEHMET,ÜNAL Ali,AKGÜN ÇAĞLIYAN GÜLSÜM,Bilgir Oktay,ilhan osman,Gediz Fusun,KAYA Emin,Sahin Fahri,vural filiz,SAYDAM Güray Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. Turkish Journal of Hematology, vol.34, no.1, 2017, ss.27 - 33.
AMA	SOYER N,HAZNEDAROĞLU İ,Cömert M,ÇEKDEMIR D,YILMAZ M,ÜNAL A,AKGÜN ÇAĞLIYAN G,Bilgir O,ilhan o,Gediz F,KAYA E,Sahin F,vural f,SAYDAM G Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. Turkish Journal of Hematology. 2017; 34(1): 27 - 33.
Vancouver	SOYER N,HAZNEDAROĞLU İ,Cömert M,ÇEKDEMIR D,YILMAZ M,ÜNAL A,AKGÜN ÇAĞLIYAN G,Bilgir O,ilhan o,Gediz F,KAYA E,Sahin F,vural f,SAYDAM G Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms. Turkish Journal of Hematology. 2017; 34(1): 27 - 33.
IEEE	SOYER N,HAZNEDAROĞLU İ,Cömert M,ÇEKDEMIR D,YILMAZ M,ÜNAL A,AKGÜN ÇAĞLIYAN G,Bilgir O,ilhan o,Gediz F,KAYA E,Sahin F,vural f,SAYDAM G "Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms." Turkish Journal of Hematology, 34, ss.27 - 33, 2017.
ISNAD	SOYER, Nur vd. "Multicenter Retrospective Analysis of Turkish Patients with Chronic Myeloproliferative Neoplasms". Turkish Journal of Hematology 34/1 (2017), 27-33.